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1. INTRODUCTION 
The present report is the ninth Commission report on the development, validation and legal 
acceptance of alternative methods to animal tests in the field of cosmetics1. It has a twofold 
purpose: 
• It is the yearly report in accordance with Article 9 of Council Directive 76/768/EEC 
of 27 July 1976 on the approximation of the laws of the Member States relating to 
cosmetic products (hereinafter “Cosmetics Directive”).2 In this regard it reflects the 
data on the number and type of experiments on animals relating to cosmetic products 
in 2009, as well as progress made in the development, validation and acceptance of 
alternative methods to animal testing in the Union and internationally.  
• In addition, it informs the European Parliament and the Council that for technical 
reasons full replacement of the animal tests covered by the 2013 deadline will not be 
achieved before 11 March 2013.3. The report therefore fulfils the first part of the 
Commission obligation under Article 4a 2.3 of the Cosmetics Directive. This 
provision tasks the Commisssion to "inform the European Parliament and the 
Council" and to "put forward a legislative proposal in accordance with Article 251 of 
the Treaty" if the Commission analysis concludes by 2011 "that for technical reasons 
one or more tests referred to in paragraph 2.1 will not be developed and validated 
before the expiry of the period referred to in paragraph 2.1". This report does not 
prejudice how the Commission will respond to the second part, i.e. the decision how 
to address the lack of non-animal tests. 
2. COMPLIANCE WITH THE TESTING AND MARKETING BAN 
The Cosmetics Directive foresees a phasing-out of animal testing for cosmetics. A ban of 
animal testing of finished cosmetic products has been in force since September 2004 and a 
testing ban on ingredients or combinations of ingredients since March 2009. As from March 
2009, it is also prohibited in the EU to market cosmetic products and their ingredients which 
                                                 
1 It is the fifth report following the 7th Amendment of the Cosmetics Directive 
2 Council Directive of 27 July 1976 on the approximation of the laws of the Member States relating to 
cosmetic products, OJ L 262, 27.9.1976, p. 169. 
3 For earlier indications see already the 'Report for establishing the timetable for phasing out animal 
testing for the purpose of the Cosmetics Directive' 
http://ec.europa.eu/consumers/sectors/cosmetics/documents/animal-testing/index_en.htm 
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have been tested on animals, irrespective of the origin of these products. This marketing ban 
applies to all but the most complex human health effects to be tested to demonstrate the safety 
of cosmetic products (repeated-dose toxicity including skin sensitisation and carcinogenicity, 
reproductive toxicity and toxicokinetics), for which the legislator extended the deadline to 
March 2013. 
2.1. Animal Testing Data 
For the present report, all Member States supplied information on animal tests carried out for 
the safety of cosmetic products in 2009. Given that the testing ban for ingredients applies as 
of 11 March 2009, testing in line with the Cosmetics Directive was only possible between 1 
January 2009 and 10 March 2009. In total, 344 animals were used in 2009 for tests carried out 
in relation to the safety of cosmetic ingredients (Table 1). In the previous years, when testing 
was allowed during the entire period, the figures were 1.818 for 2007 and 1.510 for 2008.  
According to the information received, cosmetic ingredients have only been tested on animals 
in Spain and France. These Member States provided detailed information, including the 
testing period, the toxicological endpoint, species of animals used for experiments and 
number of animals used for testing (Table 2). The other 25 Member States reported that no 
such animal tests were performed in their territory in 2009. 
Number of animals used in Member States (2009) – Table 1 
 NUMBER OF 
ANIMALS USED 
ANIMALS USED 
SPAIN 42 Rabbits 
FRANCE  302 Rat, rabbit, guinea-pigs 
Total 344  
Number of Animals Used in Relation to Toxicological Endpoints (2009) – Table 2 
TYPES OF TESTS / COUNTRIES SPAIN FRANCE 
Skin irritation 24 12 
Eye irritation 18 3 
Skin sensitisation  175 
Non-lethal toxicity  72 
Other  40 
2.2. Control and surveillance of the testing and marketing ban 
The performance of animal testing is closely controlled in Member States and this control will 
be further strengthened as of 1 January 2013 by Directive 2010/63/EU of the European 
Parliament and of the Council of 22 September 2010 on the protection of animals used for 
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scientific purposes4. One case of suspected testing after the deadline of 11 March 2009 was 
reported, which was given the respective follow-up by the responsible authorities. 
In relation to the marketing ban, Member States reported that they actively used the market 
surveillance instruments in place in order to enforce this ban. The main tool mentioned is the 
control of the product information file in accordance with Article 7a 1. (h) of the Cosmetics 
Directive. Controlling the provisions in relation to the testing and marketing ban is part of a 
check list agreed by Member States for the control of product files. Some Member States 
reported that they particularly drew the attention of the market surveillance authorities to the 
bans and provided training. Based on the experiences gathered so far Member States did not 
encounter infringements of the marketing ban.  
Member States however also pointed out that ensuring strict market surveillance remains a 
challenge, considering the limited resources and the risk that manufacturers would include 
less information in product information file in order to avoid making reference to animal 
testing data.  
3. PROGRESS IN THE DEVELOPMENT, VALIDATION AND LEGAL ACCEPTANCE OF 
ALTERNATIVE METHODS 
3.1. In the European Union  
3.1.1. Availability of alternatives for the endpoints falling under the 2009 deadline 
Endpoints falling under the 2009 deadline of the marketing ban are : skin corrosivity; skin 
irritation; dermal absorption; mutagenicity/genotoxicity; phototoxicity; acute toxicity; and eye 
irritation5.  
Full replacement alternative methods are currently available for skin corrosivity, skin 
irritation, dermal absorption, and phototoxicity, while eye irritation, acute toxicity and 
mutagenicity/genotoxicity are only covered by partial replacement methods. For these 
endpoints the marketing and the testing ban apply fully, thus unlike for the 2013 endpoints it 
is not possible to rely on data generated outside the Europan Union, so that industry has to 
rely on existing data.  
Commission Regulation (EC) 440/2008 brings together all regulatory accepted test methods 
in relation to the 2009 endpoints. An overview of regulatory accepted test methods is 
available through the Tracking System for Alternative test methods Review, Validation and 
Approval in the Context of EU Regulations on Chemicals (TSAR)6. None of the relevant 
animal tests is specific for cosmetics and none of the alternative methods validated so far was 
solely applicable to cosmetic ingredients either. Annex IX of the Cosmetics Directive 
therefore has not been amended and does not list any specific alternative methods.  
The responsible scientific committee of the European Commission, the Scientific Committee 
on Consumer Safety (SCCS), has recently adopted an updated version of its "Notes of 
                                                 
4 Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the 
protection of animals used for scientific purposes, OJ L 276, 20.10.2010, p. 33 
5 See Timetable established in 2004, SEC(2004) 1210, 
http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/sec_2004_1210_en.pdf 
6 http://tsar.jrc.ec.europa.eu/ 
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Guidance"7, in which it also describes the use of alternative methods in the safety assessment. 
In June 2010, it issued an opinion setting out "Basic criteria for the in vitro assessment of 
dermal absorption of cosmetic ingredients"8. 
 
3.1.1.1 mutagenicity/genotoxicity 
In relation to mutagenicity/genotoxicity, the in vitro tests are not optimal yet as they are too 
sensitive and may lead to an undue limitation of ingredients. For this reason, the European 
Centre for the Validation of Alternative Methods of the Joint Research Centre (ECVAM) is 
working on improving the current battery of in vitro tests. The European Cosmetics 
Association (Colipa) is focusing on the development of genotoxicity assays based on 3D 
human skin models and on a human skin metabolism programme focussed on safety 
assessment of topically applied substances. 
3.1.1.2 Eye irritation and acute toxicity 
For eye irritation and acute toxicity, several assays were validated by ECVAM, however none 
of them taken individually can fully replace animal testing in risk assessment. Testing 
strategies which combine the validated assays are currently under development and 
evaluation. Further results are expected in 2011. For acute toxicity, a previously validated test 
method was evaluated with regard to its capacity to identify substances with an LD50 > 2000 
mg/kg. The study is currently under peer review by the ECVAM Scientific Advisory 
Committee. 
3.1.2. Availability of alternatives for the endpoints falling under the 2013 implementation 
date 
The Commission engaged wide expertise and public input for its assessment of the 
availability of alternatives for the endpoints falling under the 2013 implementation date. 
Stakeholders (industry, non-governmental organisations), as well as EU Member States and 
the SCCS were invited to propose scientific experts. The selected experts analysed, under the 
co-ordination of ECVAM, the status and prospects of alternative methods. They were also 
asked to provide realistic estimates of the time required for the development of such methods 
(where they did not already exist) to a level approaching readiness for validation; i.e. meeting 
the criteria to enter pre-validation9. To allow broad input the Commission carried out a public 
consultation between 23 July and 15 October 201010 on the draft report drawn up by the 
experts. The summary of the outcome of the public consultation is accessible on the 
Commission's website11. While the majority of respondents agreed with the overall 
conclusions of the report, some consider that the available methods are already sufficiently 
                                                 
7 The SCCS'S Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, 7th 
Revision, SCCS/1416/11, 
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_004.pdf 
8 SCCS/1358/10 http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_002.pdf 
9 Pre-validation is a small-scale inter-laboratory study to assess the readiness of a test for inclusion in a 
formal large scale validation study 
10 http://ec.europa.eu/consumers/sectors/cosmetics/documents/public_consultation/index_en.htm 
11 See: http://ec.europa.eu/consumers/sectors/cosmetics/documents/animal-testing/index_en.htm 
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advanced to allow for the safety assessment of cosmetics and that not enough emphasis was 
placed on the predictivity of the available alternative methods12.  
The result is the expert report "Alternative (Non-Animal) Methods for Cosmetics Testing: 
Current Status and Future Prospects – 2010" (hereinafter "the technical report"), which is 
available on the Commission's website13 and is also published in a peer reviewed journal14. 
This report contains a detailed overview of the alternative methods currently under 
development.  
3.1.2.1. Repeated Dose Toxicity 
Repeated dose toxicity occurs if a persistent or progressively deteriorating dysfunction of 
cells, organs or multiple organ systems, results from long-term repeated exposure to a 
chemical. 
Alternative methods have so far been developed mainly with the aim of producing stand-alone 
methods predicting effects in specific target organs. In vitro models in relation to six of the 
most common targets for repeated dose toxicity (liver, kidney, central nervous system, lung, 
cardiovascular and haematopoietic system) exist. However, for the purpose of quantitative 
risk assessment, an integrated approach, e.g. based on the understanding of the mode of action 
and perturbation of biological pathways leading to toxicity, is needed.  
In addition to in vitro techniques, initial attempts of computer-based modelling techniques 
have suggested the feasibility of developing models providing meaningful predictions of 
chronic or repeated dose toxicity. At present, a few such models are available. In addition, so-
called "omics"-technologies have been developed in recent years for the purpose of 
understanding, and ultimately predicting toxicity. 
The majority of these tests and tools are however at the research and development level. 
While these methods may be useful for hazard identification of target organ toxicity or for 
obtaining mechanistic information, none of them is currently seen as appropriate for 
quantitative risk assessment for repeated dose toxicity. An integrated approach needs to be 
developed. 
To address the lack of methods replacing animal tests in the assessment of toxic effects of 
chronic exposure, the Commission launched a EUR 25 million research initiative entitled 
“Towards the replacement of repeated dose systemic toxicity testing in human safety 
assessment”15. As a result, 7 new research projects in this field have started in January 2011. 
These projects will closely cooperate to lay the scientific foundation for future safety testing 
methods with a higher predictive value, faster and cheaper than animal tests. They will 
combine the research efforts of over 70 European universities, public research institutes and 
companies. Colipa has committed to contribute to these projects by an additional EUR 25 
million.  
                                                 
12 See for example BUAV, Meeting the Deadline of the 2013 EU Marketing Ban. A Scientific Review of 
Non-Animal Tests for Cosmetics, 2011. 
13 See http://ec.europa.eu/consumers/sectors/cosmetics/documents/animal-testing/index_en.htm 
14 "Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010" in 
Archives of Toxicology: Volume 85, Issue 5 (2011), Page 367  
15 FP7-Health-2010-Alternative Testing 
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In conclusion, it is estimated that methods for full animal replacement with regulatory 
accepted tests/strategies will not be available by 2013. As full replacement for repeated dose 
toxicity is extremely challenging the experts could not provide a clear timeline by when they 
expect this to be possible. 
One specific endpoint to assess repeated dose toxicity, is skin sensitisation. This is the 
toxicological endpoint associated with chemicals that have the intrinsic ability to cause skin 
allergy. 
Several non-animal methods are being developed for hazard identification; but data from 
these test methods alone will not be sufficient for risk assessment decision-making as they do 
not provide potency information. Full replacement of the current in vivo assays will not 
require mimicking all mechanistic steps of skin sensitisation. However, at present it is not 
possible to predict which combinations of assays are needed to derive potency information for 
individual chemicals and exposure scenarios. Consequently, a tool box covering a range of 
mechanistic steps has been reviewed which could provide the required information. Previous 
efforts by Colipa have led to the successful development of three in vitro test methods for the 
detection of potential sensitisers16. At present, there are nine ongoing research and method 
development projects at Colipa in this area. 
In conclusion, the view of the experts is that in 2013 no full replacement of in vivo methods 
will be available. By 2017-2019 the experts expect the scientific ability to generate the 
necessary information for making skin sensitisation risk assessment decisions using a toolbox 
of non-animal test methods. Hazard identification without potency information might be 
possible earlier, allowing for the identification of non-sensitisers. 
Another specific endpoint on repeated dose toxicity is carcinogenicity. Carcinogenesis is a 
complex long-term multi-factorial process, and consists of a sequence of stages. Carcinogens 
have conventionally been divided into two categories according to their presumed mode of 
action: genotoxic carcinogens that affect the integrity of the genome by interacting with DNA 
and/or the cellular apparatus, and non-genotoxic carcinogens that exert their carcinogenic 
effects through other mechanisms. 
A combination of shorter-term in vitro and in vivo studies, including genotoxicity assays, is 
accepted to provide sufficient information for assessing the genotoxic potential of substances. 
Repeated dose (typically 90-day) toxicity studies are required to assess the risk of non-
genotoxic chemicals. 
Several in vitro short-term tests at different stages of development and acceptance are 
available. However, they will currently not be sufficient to fully replace the animal tests 
needed to confirm the safety of cosmetic ingredients. The current alternatives are focused on 
hazard evaluation only and cannot be used currently to support a risk assessment with the 
necessary quantitative dose-response information. However, for some chemical classes the 
available non-animal methods might be sufficient to rule out carcinogenic potential in a 
weight of evidence approach. 
                                                 
16 The direct peptide reactivity assay (DPRA), the human Cell Line Activation Test (h-CLAT) and the 
Myeloid U937 Skin Sensitisation Test (MUSST) 
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The experts conclude that alternatives will not be available by 2013 and they are unable to 
suggest a timeline for full replacement of animal tests currently needed to fully evaluate 
carcinogenic risks of chemicals.  
3.1.2.2. Reproductive Toxicity 
Reproductive toxicity refers to a wide variety of adverse effects that may occur in different 
phases within the reproductive cycle, as a consequence of one or more exposures to a toxic 
substance, including effects on fertility, sexual behaviour, embryo implantation, 
embryonic/foetal development, parturition, postnatal adaptation, and subsequent growth and 
development into sexual maturity. 
Among the various stages in the reproductive cycle, embryo-foetal development is considered 
as one of the most critical steps. Substantial effort has been spent in the development of 
promising in vitro assays, such as the Zebrafish embryo test and pluripotent embryonic stem 
cell models, to allow for the detection of the teratogenic potential of substances. However, 
besides their current role as mechanistic support and screening tools, the role of alternative 
methods as part of integrated testing strategies for regulatory toxicity evaluations has to be 
defined further. 
The complexity of mammalian reproduction requires integrated testing strategies to be able to 
fulfil all needs for hazard identification and risk assessment. A promising way forward is the 
use of recently established comprehensive databases in which toxicological information 
derived from standardised animal experimentations is collected. 
The experts estimate that the development of a testing strategy will need more than 10 years 
to complete. 
3.1.2.3. Toxicokinetics 
Toxicokinetics informs about the penetration into and fate within the body of a toxic 
substance, including its absorption, distribution, metabolism (producing less toxic metabolites 
(detoxification) or in some cases more toxic metabolites) and excretion. 
Toxicokinetics is an essential and central body of information for non animal testing strategies 
for systemic toxicity. A whole array of in vitro/in silico methods at various levels of 
development is available for most of the steps and mechanisms which govern the 
toxicokinetics of cosmetic substances. Some of these were subject of EU funded projects, 
such as Predict-IV. By constrast, for excretion no in vitro/in silico methods are available. In 
addition, there is a lack of experience for absorption through the lung alveoli, which calls for 
strengthening relevant research and development given the fact that this route of exposure is 
important for cosmetics.  
The experts estimate that alternative methods to predict renal and biliary excretion, as well as 
absorption in the lungs need at least 5 to 7 years of development. However, the development 
of an integrated approach, linking the results from in vitro/in silico methods through 
toxicokinetics in silico modelling towards the full replacement of animals will take even more 
time. 
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3.2. At International Level 
The Commission has put the issues of validation and regulatory acceptance of alternative 
methods high on its agenda of sectoral regulatory dialogues at both multilateral and bilateral 
level. 
3.2.1. Multilateral level 
The Commission continues to actively work with its counterparts from the United States, 
Japan and Canada in the framework of the "International Cooperation on Cosmetic 
Regulation" (“ICCR”). In this context, the International Cooperation on Alternative Test 
Methods (ICATM) that started in September 2008, was implemented in April 2009 by a 
Memorandum of Cooperation and has in the meantime been well established. ICATM 
members cooperate actively on the validation of alternatives and provide regular reporting to 
ICCR. Since March 2011 ICATM includes also the South Korean validation body. 
In addition to these efforts, the Commission takes a leading role in promoting the 
development and validation of alternative test methods within the Organisation for Economic 
Co-operation and Development (OECD).  
In 2010 the OECD adopted alternative test method guidelines and guidance document based 
on validation studies and evaluations by the validation bodies of ICATM in the area of dermal 
irritation (a new TG 439 for three in vitro test methods), genetic toxicity (a new TG 487 for 
the in vitro micronucleus test method), as well as reduction and refinement methods in the 
area of skin sensitisation and in the area of oral acute toxicity. Several international validation 
studies are ongoing by ICATM organizations. 
3.2.2. Bilateral level 
Questions of validation and regulatory acceptance of alternative methods are also at the core 
of the various bilateral regulatory dialogues with the main trading partners. This is in 
particular the case with the United States and Japan, who are also ICCR partners. Much 
emphasis is placed on this subject in the bilateral contacts with China. 
4. CONCLUSION 
The overall conclusion and outlook is positive when looking at the developments since 2003, 
when the current provisions were introduced. Animal testing for cosmetics purposes in the 
European Union is once and for all a thing of the past. The testing ban is well implemented 
and controlled. The number of animals used has decreased over the years to the number 344 
registered for the first months of 2009, before the full testing ban entered into force. 
Regarding the 2009 deadline, of the seven endpoints relevant for cosmetic products safety, 
replacement alternative methods are currently available for five. For 
mutagenicity/genotoxicity existing methods are being improved. For the two remaining 
endpoints, “eye irritation” and “acute toxicity”, progress is being made.  
Regarding the 2013 deadline, validated alternative methods will not be available for either of 
the three toxicological endpoints before the marketing ban enters into force. Thanks to serious 
efforts, a number of partial replacement methods are available. However, full replacement 
does not seem possible yet.  
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Progress has also been made in international cooperation, where the European Union is now 
building trust in alternative methods and joins resources with international partners in the 
validation of methods. A positive development is also the strengthening of the overall 
framework in relation to animal testing through the adoption of Directive 2010/63/EU on the 
protection of animals used for scientific purposes, which notably reinforced the role of 
validation and of ECVAM. The current report also shows that significant resources were and 
continue to be made available for research17 and that the cosmetics industry is taking an active 
and contributing role. 
The Commission is currently thoroughly assessing the potential impacts of the situation set 
out in this report on the animal welfare, on the safety of cosmetic products available to 
consumers in the EU and on the social and economic context18. It is looking at all options and 
will make a decision based on the results of the said impact assessment as to whether or not to 
make a proposal to the European Parliament and the Council in relation to the implementation 
date 2013. 
 
                                                 
17 For an overview of research efforts in this area see: Alternative Testing Strategies – Progress Report 
2010, Replacing, Reducing and refining use of animals in research (http://axlr8.eu/axlr8-2010-progress-
report.pdf) 
18 See input received from a targeted stakeholder consultation under: 
http://ec.europa.eu/consumers/sectors/cosmetics/documents/animal-
testing/stakeholders_consultation_en.htm 
